Sushil Sharma

The Charnolosome as a Novel Nanothereranostic Biomarker

Overcoming Future Challenges in Medicine

• Broschiertes Buch

Produktbeschreibung

The Charnolosome as a Novel Nanothereranostic Biomarker: Overcoming Future Challenges in Medicine provides an overview of the charnolosome and its potential as a biomarker of cell injury. Based on the author’s original discovery of the charnoly body in the developing, undernourished rat cerebellar Purkinje neurons, this book delves into the potential for utilizing this mitochondria and lysosomal-derived intracellular organelle as a nanotheranostic biomarker to prevent and cure various diseases. The book discusses the cellular, molecular, genetic, and epigenetic mechanisms of charnolosomes and charnolosome-derived nano-vesicles. It also investigates the molecular mechanisms underlying auto-inflammatory, autoimmune, and infectious diseases resulting from their compromised mitochondrial bioenergetics, and the potential use of the charnolosome in preventing and curing such conditions.

Produktdetails

• Verlag: Elsevier Health Sciences
• Seitenzahl: 500
• Erscheinungstermin: 1. September 2024
• Englisch
• ISBN-13: 9780443217524
• ISBN-10: 0443217521
• Artikelnr.: 69925862

Autorenporträt

Academic Dean Sushil Sharma works at the American International School of Medicine in Georgetown, Guyana, USA.

Inhaltsangabe

Section I: General Topics 1. Transcriptional regulation of Charnolosome
through gene/base-editing 2. Charnolosome destabilization induces
inflammasome activation 3. Charnolosome in Charnoly Body molecular
pathogenesis of gene-manipulated cells and animals 4. Charnolosome and
inflammasome in chronic MDR diseases 5. Charnolosome stabilization inhibits
inflammasome to confer personalized nanotheranostic benefit in chronic MDR
diseases 6. Endogenous, natural, and synthetic antioxidants stabilize
charnolosome and its exocytosis to confer theranostic benefit by
inflammasome inhibition 7. Charnolosome stability index (stabilized
Charnolosome vs activated inflammasome) determines normal cellular function
to remain healthy 8. Charnolosome stability index regulates Charnoly Body
molecular pathogenesis 9. Nanotheranostic significance of antioxidants in
Charnolosome detoxification 10. Theranostic significance of Charnolosome in
personalized nanomedicine 11. Environmental toxins and transcriptional
regulation of Charnolosome 12. Antioxidants-mediated Charnolosome
transcriptional regulation in health and disease 13. Mitochondrial
bioenergetics, Charnosome, and theranostic potential of antioxidants 14.
Cellular, molecular, and genetic significance of metallothioneins as
Charnolosome modulators 15. Pharmacogenomics of metallothioneins and other
endogenous, natural, and synthetic antioxidants as CS Regulators in health
and disease 16. Environmental pollution and metal ion speciation of
metallothioneins 17. Metallothioneins as potential
charnolopharmacotherapeutics 18. Antioxidants as Charnolosome stabilizers,
charnolophagy enhancers, and intracellular detoxifiers. 19.
Charnolosomaging triggers inflammaging to induce charnoptosis, pyroptosis,
and ferroptosis in chronic MDR diseases in aging 20. Charnolosome as a
theranostic biomarker in cell therapy and nanomedicine Section II: Special
Topics Part 1: Malnutrition, Stress, Inflammation, Microbial Infections,
and Ionizing Radiation Injuries 21. Charnolosome in malnutrition 22.
Charnolosome in stress 23. Charnolosome in inflammation 24. Charnolosome in
microbial infections 25. Charnolosome in ionizing radiation injuries Part
2: Congenital & Metabolic Diseases 26. Charnolosome in congenital diseases
27. Charnolosome in metabolic diseases 28. Charnolosome in hyperlipidemia
29. Charnolosome in obesity 30. Charnolosome in diabetes 31. Charnolosome
in hepatic diseases 32. Charnolosome in GIT diseases Part 3:
Multidrug-Resistant Systemic Diseases 33. Charnolosome in skin diseases 34.
Charnolosome in musculo-skeletal diseases 35. Charnolosome in pulmonary
diseases 36. Charnolosome in cardiovascular diseases 37. Charnolosome in
renal diseases 38. Charnolosome in reproductive diseases Part 4:
Neuropsychiatric & Neurodegenerative Diseases 39. Charnolosome in
polysubstance abuse 40. Charnolosome in neuropsychiatric diseases 41.
Charnolosome in neurodegenerative diseases 42. Charnolosome in
Neurodegenerative a-Synucleinopathies 43. Charnolosome in Parkinson's
Disease 44. Charnolosome in Alzheimer's Disease and other taupathies 45.
Charnolosome in stroke & traumatic brain injury 46. Attenuation of
Charnolosome-Mediated Neurodegenerative a-Synucleinopathies by antioxidants
47. Charnolosome as a novel nanotheranostic biomarker of aging Part 5:
Inflammatory Diseases, Autoimmune Diseases, Cancer, & Infectious Diseases
48. Charnolosome in Inflammatory Diseases 49. Charnolosome in autoimmune
diseases 50. Charnolosome in cancer 51. Charnolosome in infectious diseases
Section III: Future Prospects 52. Charnolosomics in nanomedicine (Recent
Update) 53. Charnolosome-based disease-specific nanopharmacotherapeutics
54. Physiological, Biochemical, Pharmacological, and Genetic Manipulation
of Charnolosome in Personalized Nanotheranostics of Chronic MDR Diseases
55. Transcriptional and translational regulation of Charnolosome in
multi-drug resistant malignancies and other chronic diseases 56. Future
prospectus of Charnolosome in evidence-based personalized nanotheranostics